{"id":47057,"date":"2025-11-12T22:09:14","date_gmt":"2025-11-12T14:09:14","guid":{"rendered":"https:\/\/flcube.com\/?p=47057"},"modified":"2025-11-12T22:09:16","modified_gmt":"2025-11-12T14:09:16","slug":"walvax-biotechnology-pharmaniaga-lifescience-forge-malaysia-partnership-for-pcv%e2%80%9113-production-and-distribution","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47057","title":{"rendered":"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution"},"content":{"rendered":"\n<p><strong>Walvax Biotechnology Co., Ltd.<\/strong> and <strong>Pharmaniaga Lifescience Sdn.\u202fBhd.<\/strong> (wholly\u2011owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the <strong>13\u2011valent Pneumococcal Conjugate Vaccine (PCV\u201113)<\/strong> in Malaysia. The partnership will transfer Walvax\u2019s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-collaboration-highlights\">Collaboration Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Technology Transfer<\/strong><\/td><td>Walvax will provide production protocols, quality systems, and regulatory expertise for PCV\u201113.<\/td><\/tr><tr><td><strong>Manufacturing Hub<\/strong><\/td><td>Pharmaniaga Lifescience will operate a dedicated facility in Malaysia, meeting WHO and national standards.<\/td><\/tr><tr><td><strong>Commercialization Strategy<\/strong><\/td><td>Joint marketing, pricing, and distribution plan targeting public\u2011sector immunization programs and private healthcare providers.<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Coordinated submission to Malaysia\u2019s Ministry of Health for local approval and registration.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-pcv-13-matters\">Why PCV\u201113 Matters<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High\u2011Burden Disease<\/strong> \u2013 Pneumococcal infections cause >500,000 pneumonia\u2011related deaths worldwide each year, with infants the most vulnerable group.<\/li>\n\n\n\n<li><strong>Drug\u2011Resistant Strains<\/strong> \u2013 The vaccine targets 13 serotypes, including multiple drug\u2011resistant clones that are rising in Asia.<\/li>\n\n\n\n<li><strong>Public\u2011Health Impact<\/strong> \u2013 Introduction of PCV\u201113 can reduce national childhood morbidity and mortality while lowering healthcare costs.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied herein.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn.\u202fBhd. (wholly\u2011owned by Pharmaniaga Berhad) today announced a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":47059,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2486,12,332],"class_list":["post-47057","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-pharmaniaga-berhad","tag-vaccine","tag-walvax-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn.\u202fBhd. (wholly\u2011owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the 13\u2011valent Pneumococcal Conjugate Vaccine (PCV\u201113) in Malaysia. The partnership will transfer Walvax\u2019s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47057\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution\" \/>\n<meta property=\"og:description\" content=\"Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn.\u202fBhd. (wholly\u2011owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the 13\u2011valent Pneumococcal Conjugate Vaccine (PCV\u201113) in Malaysia. The partnership will transfer Walvax\u2019s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47057\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T14:09:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-12T14:09:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution\",\"datePublished\":\"2025-11-12T14:09:14+00:00\",\"dateModified\":\"2025-11-12T14:09:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202-1.webp\",\"keywords\":[\"Pharmaniaga Berhad\",\"Vaccine\",\"Walvax Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47057#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47057\",\"name\":\"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202-1.webp\",\"datePublished\":\"2025-11-12T14:09:14+00:00\",\"dateModified\":\"2025-11-12T14:09:16+00:00\",\"description\":\"Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn.\u202fBhd. (wholly\u2011owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the 13\u2011valent Pneumococcal Conjugate Vaccine (PCV\u201113) in Malaysia. The partnership will transfer Walvax\u2019s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47057\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47057#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution - Insight, China&#039;s Pharmaceutical Industry","description":"Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn.\u202fBhd. (wholly\u2011owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the 13\u2011valent Pneumococcal Conjugate Vaccine (PCV\u201113) in Malaysia. The partnership will transfer Walvax\u2019s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47057","og_locale":"en_US","og_type":"article","og_title":"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution","og_description":"Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn.\u202fBhd. (wholly\u2011owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the 13\u2011valent Pneumococcal Conjugate Vaccine (PCV\u201113) in Malaysia. The partnership will transfer Walvax\u2019s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.","og_url":"https:\/\/flcube.com\/?p=47057","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-12T14:09:14+00:00","article_modified_time":"2025-11-12T14:09:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47057#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47057"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution","datePublished":"2025-11-12T14:09:14+00:00","dateModified":"2025-11-12T14:09:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47057"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47057#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202-1.webp","keywords":["Pharmaniaga Berhad","Vaccine","Walvax Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47057#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47057","url":"https:\/\/flcube.com\/?p=47057","name":"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47057#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47057#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202-1.webp","datePublished":"2025-11-12T14:09:14+00:00","dateModified":"2025-11-12T14:09:16+00:00","description":"Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn.\u202fBhd. (wholly\u2011owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the 13\u2011valent Pneumococcal Conjugate Vaccine (PCV\u201113) in Malaysia. The partnership will transfer Walvax\u2019s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47057#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47057"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47057#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202-1.webp","width":1080,"height":608,"caption":"Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47057#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Walvax Biotechnology &amp; Pharmaniaga Lifescience Forge Malaysia Partnership for PCV\u201113 Production and Distribution"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47057"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47057\/revisions"}],"predecessor-version":[{"id":47060,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47057\/revisions\/47060"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/47059"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}